Corporate Office & Central Laboratory :
Survey No 9/1, Near Tulsiyana Industrial Park, Gram
Kumerdi, Indore (M.P.) 453555
Tel: +91 731 4243850 - 88
Fax: +91 731 2490593
Email: compliance_officer@choksilab.in
Website: www.choksilab.in
CIN: L85195MP1993PLC007471

CHOKSI LABORATORIES LIMITED

To,
The Corporate Relationship Department
BSE Limited
Phiroze Jeejeebhoy Tower
Dalal Street, Fort
Mumbai-Maharashtra 400001

Date: 07th February, 2026

Subject: Submission of Unaudited Financial Results along with Limited Review Report for the Quarter and Nine Month ended 31st December, 2025

Ref: Scrip Code: 526546, ISIN: INE493D01013

Dear Sir/Madam,

Pursuant to Regulation 30 & 33 of the SEBT (Listing Obligations and Disclosure Requirements) Regula lions, 2015, please find enclosed herewith the following:

1. Considered and approved **Unaudited Financial Results** along with Limited Review Reports for the Quarter and Nine Month ended on 31st December, 2025.

The aforesaid results are duly approved by the Audit Committee and Board of Directors in their respective meetings held on Saturday, 07th February 2026.

You are requested to take the same on your record.

Thanking You

Yours faithfully

For CHOKSI LABORATORIES LIMITED

PRAKHAR DUBEY
Digitally signed by PRAKHAR DUBEY
Date: 2026.02.07 14:35:46 +05'30'

PRAKHAR DUBEY
COMPANY SECRETARY &
COMPLIANCE OFFICER

Encl.: Copy of Unaudited Financial Results along with the Limited Review Report for the Quarter and Nine Month ended on 31st December, 2025

PRATEEK JAIN & CO.

CHARTERED ACCOUNTANTS
405, SHALIMAR CORPORATE CENTRE, 8-B, SOUTH TUKOGANJ,
INDORE (M.P.) 452001
PH. 9827013187, 731-3590283
E-MAIL: teamca@rediffmail.com

Independent Auditor's Review Report on the unaudited Quarterly Standalone Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations , 2015, as amended

To,
The Board of Directors
Choksi Laboratories Limited
Indore (M.P.) - 452001

We have reviewed the accompanying statement of unaudited financial results of **CHOKSI LABORATORIES LIMITED** ("the Company") for the quarter ended **December 31, 2025 and year to date results for the period from April, 01, 2025 to December 31, 2025** ("the statement") attached herewith, being submitted by the Company pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ("the listing regulations").

This statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 (Ind AS 34) "Interim Financial Reporting" prescribed under section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 (as amended) and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE 2410) *"Review of Interim Financial Information Performed by Independent auditor of the Entity"* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

PRATEEK JAIN & CO. CA INDIA FRN: 009494C INDORE Chartered Accountants

PRATEEK JAIN & CO.

CHARTERED ACCOUNTANTS
405, SHALIMAR CORPORATE CENTRE, 8-B, SOUTH TUKOGANJ,
INDORE (M.P.) 452001
PH. 9827013187, 731-3590283
E-MAIL: teamca@rediffmail.com

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in all material respect in accordance with the applicable recognition and measurement principles laid down in the aforesaid Indian Accounting Standard (Ind AS) prescribed under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other recognized accounting practices generally accepted in India, has not disclosed the information required to be disclosed in terms of Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

FOR PRATEEK JAIN AND CO.
CHARTERED ACCOUNTANTS
FRN-009494C

PRATEEK JAIIN
PROPRIETOR
M.NO.079214

Date: 7TH Feb, 2026
Place: Indore
UDIN: 26079214PUBWWF4585

Corporate Office & Central Laboratory :
Survey No. 9/1., Balaji Tulsiyana Industrial Park,
Kumedi, Off. M.R. 10 Toll Naka, Indore – 453555, M.P. (India)
Tel. +91 731 3501112 (60 Lines)
Email : bd@choksilab.com
Website : www.choksilab.in

CHOKSI LABORATORIES LIMITED
(ANALYTICAL TESTING & CALIBRATION LABORATORY GROUP)

CHOKSI LABORATORIES LIMITED

Statement of Standalone Unaudited financial Results for the Quarter and Nine Months Ended on 31st December'2025

(₹ In Lakhs)

As per Schedule III of the Companies Act, 2013

Sl. No.	Particulars	Quarter Ended on			Nine Month Ended on		Year Ended
		3 Months ended	Preceding 3 months ended	Corresponding 3 months ended in the previous year	Year to Date figures for the current period	Year to Date figures for the corresponding 9 month ended in the previous year	Year to date figures for current period ended
		31.12.2025	30.09.2025	31.12.2024	31.12.2025	31.12.2024	31.03.2025
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I	**Revenue from Operation**	1082.47	1111.71	1038.42	3318.37	3038.28	4178.23
II	**Other Income**	13.34	1.48	0.84	15.15	2.28	6.71
III	**Total Income (I+II)**	**1095.81**	**1113.19**	**1039.26**	**3333.52**	**3040.56**	**4184.94**
IV	**Expenses**						
	(a) Cost of materials consumed	88.39	70.90	80.01	243.79	229.73	309.82
	(b) Employee benefits expense	454.10	457.10	439.01	1370.44	1245.80	1697.66
	(c) Finance Cost	80.81	69.36	69.15	210.27	206.78	264.93
	(d) Depreciation and amortisation expense	183.39	168.65	167.75	519.63	479.43	649.88
	(e) Laboratories Maintainance Expenses	122.89	108.00	115.62	343.69	324.13	408.95
	(f) Power & Fuel Charges	23.21	25.95	23.64	78.71	76.54	98.77
	(g) Other expenses	130.44	156.98	125.84	435.42	388.76	539.60
	Total expenses	**1083.23**	**1056.94**	**1021.02**	**3201.95**	**2951.17**	**3969.61**
V	**Profit / (Loss) before exceptional items and tax (III-IV)**	**12.58**	**56.25**	**18.24**	**131.57**	**89.39**	**215.33**
VI	Exceptional items	(77.80)	-	-	(77.80)	-	-
VII	**Profit / (Loss) before tax (V-VI)**	**90.38**	**56.25**	**18.24**	**209.37**	**89.39**	**215.33**
VIII	**Tax Expenses**						
	(a) Current Tax	0.16	14.30	6.87	24.39	20.75	33.38
	(b) Income Tax Earlier Year	-	-	-	-	-	-
	(c) Mat Credit Entitlement	40.82	13.18	7.25	55.88	(6.63)	39.50
	(d) Deferred Tax	18.36	4.56	(6.46)	35.35	15.07	(9.88)
IX	**Net Profit / (Loss) for the period from continuing operations (VII-VIII)**	**31.04**	**24.21**	**10.58**	**93.75**	**60.20**	**152.33**
X	**Other Comprehensive Income**						
	(a) (i) Items that will not be reclassified to profit & loss	2.66	36.66	7.61	38.01	24.83	(5.23)
	(ii) Income tax relating to items that will not be reclassified to profit & loss	(0.69)	(9.53)	(1.98)	(9.88)	(6.46)	1.36
	(b) (i) Items that will be re-classified to profit & loss	0.00	(2.57)	10.05	-	34.11	(15.51)
	(ii) Income tax relating to items that will be reclassified to profit & loss	0.00	0.67	(2.61)	-	(8.87)	4.03
XI	**Total Comprehensive Income (IX+X)**	**33.01**	**49.44**	**23.65**	**121.88**	**103.81**	**136.98**
XII	**Detail of equity share capital**						
	(a) Paid-up equity share capital	696.52	696.52	696.52	696.52	696.52	696.52
	(b) Face value of equity share capital (in Rs.)	10.00	10.00	10.00	10.00	10.00	10.00
XIII	**Earnings per equity share (for continuing operations)**						
	(a) Basic	0.45	0.35	0.15	1.35	0.86	2.19
	(b) Diluted	0.45	0.35	0.15	1.35	0.86	2.19
XIV	**Earnings per equity share (for Dis-continuing operations)**						
	(a) Basic	-	-	-	-	-	-
	(b) Diluted	-	-	-	-	-	-
XV	**Earnings per equity share (for Dis-continued and continuing operations)**						
	(a) Basic	0.45	0.35	0.15	1.35	0.86	2.19
	(b) Diluted	0.45	0.35	0.15	1.35	0.86	2.19

Cont..

For Choksi Laboratories Limited

Managing Director

Corporate Office & Central Laboratory :
Survey No. 9/1., Balaji Tulsiyana Industrial Park,
Kumedi, Off. M.R. 10 Toll Naka, Indore – 453555, M.P. (India)
Tel. +91 731 3501112 (60 Lines)
Email : bd@choksilab.com
Website : www.choksilab.in

CHOKSI LABORATORIES LIMITED
(ANALYTICAL TESTING & CALIBRATION LABORATORY GROUP)

Notes to the results :

1 These results have been prepared as per Regulation 33 of the SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 and in accordance with the Indian Accounling Standards (Ind AS) notified under Section 133 of the Companies Act, 2013, read with the Companies (Indian Accounting Standards) Rules 2015 as amended and other accounting principles generally accepted in India.

2 The figures for the quarter ended on 31st December, 2025 are the balancing figures between unaudited figures in respect of the Quarter ended on December 31, 2025 and the published unaudited figures for the quarter and Half Year ended on September 30, 2025.

3 The above Financial Results for the quarter ended on 31st December 2025 have been reviewed by the Audit Committee and approved & taken on record by the Board at their Board meeting held on Saturday, 07th February 2026.

4 Depreciation on fixed assets is provided on straight line method as per the estimated remaining useful lives of assets.

5 The Company has identified "Analysis and Testing" as the single operating segment for the continued operations in the financial statements as per Ind AS 108 "Operating Segments".

6 Revenue from Operations is shown exclusive of GST

7 "Other Income" for the quarter and nine months ended on 31st December 2025 includes :-
Interest Income ₹ 0.58, Interest on IT Refund ₹ 13.26 Lakhs Cash Back on Credit Card ₹ 0.21 Lakhs, & Forex Gain ₹ 1.10 Lakhs.

8 Exceptional Item: During the quarter, the Company sold an office flat resulting in a gain of ₹77.80 Lakhs . The transaction is non-recurring in nature and does not form part of the Company's ordinary operating activities. Accordingly, the gain has been disclosed as an Exceptional Item in the Statement of Profit and Loss.

9 Figures for the previous periods have been regrouped, wherever necessary and minus figures are shown in brackets.

10 Earnings per share amount is shown in Rupees (₹).

11 For any queries email at compliance_officer@choksilab.in

For and on behalf of the Board of Directors of
CHOKSI LABORATORIES LIMITED

Sunil Choksi
Managing Director
DIN 00155078

CHOKSI LABORATORIES LTD.

Date: 07th February 2026
Place: Indore